Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab

Nivolumab, a blockade of programmed cell death 1, is now administrated for advanced malignant melanomas. Nivolumab‐associated adverse events include organ‐specific autoimmune disorders; autoimmune thyroid disease, vitiligo and insulin‐dependent diabetes. However, predisposed persons are currently un...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2016-02, Vol.43 (2), p.210-214
Main Authors: Narita, Tomohiko, Oiso, Naoki, Taketomo, Yasunori, Okahashi, Kazunori, Yamauchi, Kohei, Sato, Masako, Uchida, Shusuke, Matsuda, Hiromasa, Kawada, Akira
Format: Article
Language:English
Subjects:
Adrenal glands
Aged
Antibodies, Monoclonal - adverse effects
Autoimmune diseases
Female
Hashimoto disease
Hashimoto Disease - blood
Hashimoto Disease - etiology
Hashimoto Disease - immunology
Humans
insulin-dependent diabetes
Male
malignant melanoma
Melanoma - secondary
Melanoma - therapy
nivolumab
Thyroid diseases
Thyroid Gland - diagnostic imaging
Thyroid Hormones - blood
Ultrasonography
vitiligo
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nivolumab, a blockade of programmed cell death 1, is now administrated for advanced malignant melanomas. Nivolumab‐associated adverse events include organ‐specific autoimmune disorders; autoimmune thyroid disease, vitiligo and insulin‐dependent diabetes. However, predisposed persons are currently unknown. Here, we report serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab: one with Hashimoto disease and another with probable subclinical Hashimoto disease. We should verify if nivolumab‐related hypothyroidism and hyperthyroidism are predisposed to occur in euthyroid individuals with subclinical autoimmune thyroid disease.
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.13028